Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preface.

Nicolle1, Wise, Wood

  • 1Vienna, Austria, March 2000.

The Journal of Antimicrobial Chemotherapy
|September 2, 2000
PubMed
Summary
This summary is machine-generated.

Urinary tract infections (UTIs) are common, with increasing antibiotic resistance necessitating new treatment strategies. Pivmecillinam shows promise for effective UTI treatment due to its unique action and safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digitalis in Heart Diseases.

Atlanta medical and surgical journal·2022
Same author

Wood and Trees attend a conference.

Journal of the Intensive Care Society·2019
Same author

May the force be with you.

Journal of the Intensive Care Society·2018
Same author

Lemmingaid.

Journal of the Intensive Care Society·2018
Same author

Lost youth.

Journal of the Intensive Care Society·2017
Same author

General Paralysis of the Insane.

The Indian medical gazette·2017
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Area of Science:

  • Urology
  • Infectious Diseases
  • Pharmacology

Background:

  • Lower urinary tract infections (UTIs) are a common condition, accounting for significant general practitioner consultations and antibiotic prescriptions.
  • Uropathogenic bacteria are developing resistance to widely used antibiotics like trimethoprim and ampicillin, often exceeding 30-50% resistance rates.
  • Rapid development of resistance to fluoroquinolones, a common alternative, poses further treatment challenges.

Purpose of the Study:

  • To review current perspectives on the diagnosis and treatment of UTIs in light of evolving microbial resistance patterns.
  • To reevaluate treatment options for UTIs, considering the challenges posed by antimicrobial resistance.
  • To assess the potential role of pivmecillinam in managing UTIs.

Main Methods:

Related Experiment Videos

  • The supplement is based on papers presented at a meeting in Vienna, Austria, sponsored by Leo Pharmaceutical Laboratories.
  • It synthesizes current views on UTI diagnosis and treatment.
  • Clinical data and pharmacological properties of pivmecillinam were considered.

Main Results:

  • Antibiotic resistance to common UTI treatments is high.
  • Fluoroquinolone resistance can emerge rapidly.
  • Pivmecillinam exhibits a novel mode of action, rapid bacterial penetration, and lower affinity for beta-lactamases.

Conclusions:

  • Pivmecillinam's spectrum of activity and safety profile make it a suitable candidate for UTI treatment.
  • Long-term experience in several countries supports the efficacy of pivmecillinam.
  • Reconsideration of pivmecillinam's role in UTI treatment is warranted.